D. T. Chen, Y.-L. Hsu, W. J. Fulp, et al., “Prognostic and Predictive Value of a Malignancy-Risk Gene Signature in Early-Stage Non-Small Cell Lung Cancer,” Journal of the National Cancer Institute, Vol. 103, No. 24, 2011, pp. 1859-1870. http://dx.doi.org/10.1093/jnci/djr420
 T. A. D’Amico, M. Massey, J. E. Herndon, et al., “A Biologic Risk Model for Stage I Lung Cancer: Immunohistochemical Analysis of 408 Patients with the Use of Ten Molecular Markers,” The Journal of Thoracic and Cardiovascular Surgery, Vol. 117, No. 4, 1999, pp. 736-743. http://dx.doi.org/10.1016/ S0022-5223(99)70294-1
 S. Y. Park, H. S. Lee, H. J. Jang, et al., “Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer,” The Annals of Thoracic Surgery, Vol. 91, No. 6, 2011, pp. 1668-1673.
 B. A. Williams, H. Sugimura, Ch. Endo, et al., “Predicting Postrecurrence Survival Among Completely Resected Nonsmall-Cell Lung Cancer Patients,” The Annals of Thoracic Surgery, Vol. 81, No. 3, 2006, pp. 1021-1027. http://dx.doi.org/10.1016/j.athoracsur.2005.09.020
 W. Hilbe, S. Dirnhofer, F. Oberwasserlechner, et al., “Immunohistochemical Typing of Non-Small Cell Lung Cancer on Cryostat Sections: Correlation with Clinical Parameters and Prognosis,” Journal of Clinical Pathology, Vol. 56, No. 10, 2003, pp. 736-741. http://dx.doi.org/10.1136/jcp.56.10.736
 D. J. Raz, M. R. Ray, J. Y. Kim, et al., “A Multigene Assay Is Prognostic of Survival in Patients with EarlyStage Lung Adenocarcinoma,” Clinical Cancer Research, Vol. 14, No. 17, 2008, pp. 5565-5570. http://dx.doi.org/10.1158/1078-0432.CCR-08-0544
 C. Lu, J.-Ch. Soria, X. Tang, et al., “Prognostic Factors in Resected Stage I Non-Small-Cell Lung Cancer: A Multivariate Analysis of Six Molecular Markers,” Journal of Clinical Oncology, Vol.22, No. 22, 2004, pp. 4575-4583. http://dx.doi.org/10.1200/JCO.2004.01.091
 D. H. Harpole, Jr. J. E. Herndon, W. G. Wolfe, et al., “A Prognostic Model of Recurrence and Death in Stage I Non-Small Cell Lung Cancer Utilizing Presentation, Histopathology, and Oncoprotein Expression,” Cancer Research, Vol. 55, No. 1, 1995, pp. 51-56.
 A. Lopez-Encuentra, Lopez-Rios, E. Conde et al., “Composite Anatomical-Clinical-Molecular Prognostic Model in Nonsmall Cell Lung Cancer,” European Respiratory Journal, Vol. 31, No. 7, 2011, pp. 136-142. http://dx.doi.org/10.1183/09031936.00028610
 C. Q. Zhu, W. Shih, C. H Ling and M. S. Tsao, “Immunohistochemical Markers of Prognosis in Non-Small Cell Lung Cancer: A Review and Proposal for a Multiphase Approach to Marker Evaluation,” Journal of Clinical Pathology, Vol. 59, No. 8, 2006, pp. 790-800. http://dx.doi.org/10.1136/jcp.2005. 031351
 L. R. Leonardus, van der Pijl, O. Birim, et al., “Validation of a Prognostic Model to Predict Survival after NonSmall-Cell Lung Cancer Surgery,” European Journal of Cardio-Thoracic Surgery, Vol. 38, No. 5, 2010, pp. 615-620. http://dx.doi.org/10.1016/j.ejcts.2010.03.028
 H. Dosaka-Akita, F. Hommura, T. Mishina, et al., “A Risk-Stratification Model of Non-Small Cell Lung Cancers Using Cyclin E, Ki-67, and rasp21: Different Roles of G1 Cyclins in Cell Proliferation and Prognosis,” Cancer Research, Vol. 61, 2001, pp. 2500-2504.
 L. Rubio, F. J. Vera-Sempere, J. A. Lopez-Guerrero, et al., “A Risk Model for Non-Small Cell Lung Cancer Using Clinicopathological Variables, Angiogenesis and Oncoprotein Expression,” Anticancer Research, Vol. 25, No. 1B, 2005, pp. 497-504.